NeuroMetrix

About NeuroMetrix

NeuroMetrix, Inc., a healthcare company established in 1996, operates as a commercial-stage entity focused on non-invasive medical devices for neurological disorders and pain syndromes. The company was founded by Shai N. Gozani, M.D., Ph.D., as a spin-off from the Harvard-MIT Division of Health Sciences and Technology. Dr. Gozani's extensive background, which includes a B.A. in computer science, an M.S. in Biomedical Engineering, a Ph.D. in Neurobiology from the University of California, Berkeley, and an M.D. from Harvard Medical School, has been foundational to the company's direction. His research in neurophysiology, biomedical engineering, and computational chemistry has directly shaped the company's technological advancements.

The company's business model is centered on developing and commercializing medical devices that often utilize a proprietary consumable component, with a significant portion of revenue generated from these aftermarket sales. NeuroMetrix targets healthcare providers and patients within the neurology and pain management sectors, distributing its products through a network spanning the Americas, Europe, Asia, and the Middle East. In May 2025, NeuroMetrix was acquired by electroCore, Inc., a bioelectronic medicine company, and now operates as a wholly-owned subsidiary while continuing to market its products under its established brands. The acquisition did not include the DPNCheck business, which was expected to be divested.

NeuroMetrix has two principal product lines. The first is DPNCheck, a point-of-care diagnostic device used by clinicians to assess peripheral neuropathies, particularly diabetic peripheral neuropathy (DPN). This handheld device works by measuring the nerve conduction velocity and response amplitude of the sural nerve, providing a quantitative method to detect, stage, and monitor the condition, even before symptoms appear. The second flagship product is Quell, a wearable transcutaneous electrical nerve stimulation (TENS) device. Quell is designed for the symptomatic relief and management of chronic pain. It has received FDA De Novo authorization as a treatment for reducing the symptoms of fibromyalgia in adults with high pain sensitivity, making it the first non-pharmacological treatment for this condition. The device also holds an FDA Breakthrough Device Designation for treating chemotherapy-induced peripheral neuropathy (CIPN). Quell is a wearable neuromodulator that can be used day and night and connects to a smartphone app via Bluetooth.

Significant milestones for the company include receiving FDA Breakthrough Device Designation for Quell for fibromyalgia in July 2021, followed by De Novo marketing authorization in May 2022. These regulatory achievements were based on clinical trial data demonstrating meaningful improvements in quality of life and reductions in fibromyalgia symptoms for users. The company’s strategy involves launching prescription indications for Quell, starting with fibromyalgia, and commercializing through physician offices, with a focus on rheumatologists and pain medicine specialists.